Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02018445 · ClinicalTrials.gov registry record · NA
Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion
A NA study, sponsored by SeaSpine.
- Completed
- Registry status
- NA
- Development phase
- 36
- Enrollment target
NCT02018445: Completed NA study, sponsored by SeaSpine.
NCT02018445 is a NA study that has completed, run by SeaSpine. The registered enrollment target is 36 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02018445, a NA study, has completed, sponsored by SeaSpine.
- COMPLETED
- Registry status
- NA
- Development phase
- 36 participants
- Enrollment target
Study Summary
The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented posterolateral spine fusion, as compared to local autograft.
Primary Outcome
There were 29 patients and 43 total spinal levels (unit) treated at baseline. Time to arthodesis was measured as the mean time to achieve fusion. At each time point fusion was evaluated, the first time point fusion was achieved was considered fusion.
Interventions
- PROCEDURE Posterolateral Fusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2013-11 |
| Est. Completion | 2017-05 |
| Phase | NA |
What the finished NCT02018445 record still lists
NCT02018445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Posterolateral Fusion is the first listed.
NCT02018445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02018445 about?
NCT02018445 is a clinical study titled "Accell Evo3™ Demineralized Bone Matrix in Instrumented Lumbar Spine Fusion". The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for instrumented posterolateral spine fusion, as compared to local autograft.
What is the current status of trial NCT02018445?
This trial is currently completed. It is a NA study. The enrollment target is 36 participants. The study started on 2013-11. Estimated completion is 2017-05.
What interventions are being tested in trial NCT02018445?
The interventions under investigation include: Posterolateral Fusion (PROCEDURE).
Who is sponsoring clinical trial NCT02018445?
This trial is sponsored by SeaSpine, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02018445's enrollment target sits among peer trials
36 1541st of 2000 higher than 437 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia